Drug Approval | April 21, 2026
Orbicular's partner secures tentative U.S. ANDA approval for a generic version of Ozempic
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
PMDA is regarded among the most stringent regulatory bodies globally
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
The license is valid for five years, effective from April 9, 2026
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
Subscribe To Our Newsletter & Stay Updated
